Följ
Yichen Zhong
Yichen Zhong
Verifierad e-postadress på bms.com
Titel
Citeras av
Citeras av
År
Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder–a systematic literature review
K Gajria, M Lu, V Sikirica, P Greven, Y Zhong, P Qin, J Xie
Neuropsychiatric disease and treatment, 1543-1569, 2014
2322014
The short-term impacts of the Philadelphia beverage tax on beverage consumption
Y Zhong, AH Auchincloss, BK Lee, GP Kanter
American journal of preventive medicine 55 (1), 26-34, 2018
1432018
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies
DY Heng, J Signorovitch, E Swallow, N Li, Y Zhong, P Qin, DY Zhuo, ...
PloS one 9 (12), e114264, 2014
502014
Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with …
MA Bittoni, A Arunachalam, H Li, R Camacho, J He, Y Zhong, ...
Clinical lung cancer 19 (5), e629-e645, 2018
412018
Sugar-sweetened and diet beverage consumption in Philadelphia one year after the beverage tax
Y Zhong, AH Auchincloss, BK Lee, RM McKenna, BA Langellier
International journal of environmental research and public health 17 (4), 1336, 2020
282020
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small …
A Arunachalam, H Li, MA Bittoni, R Camacho, X Cao, Y Zhong, ...
Clinical Lung Cancer 19 (5), e783-e799, 2018
262018
Nonlinear trajectory of GFR in children before RRT
Y Zhong, A Muñoz, GJ Schwartz, BA Warady, SL Furth, AG Abraham
Journal of the American Society of Nephrology 25 (5), 913-917, 2014
212014
Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy
K Patterson, V Prabhu, R Xu, H Li, Y Meng, N Zarabi, Y Zhong, R Batteson, ...
European urology oncology 2 (5), 565-571, 2019
182019
Real‐world medication persistence with single versus multiple tablet regimens for HIV‐1 treatment
D Sweet, J Song, Y Zhong, J Signorovitch
Journal of the International AIDS Society 17, 19537, 2014
172014
Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy
K Flannery, X Cao, J He, Y Zhong, AY Shah, AM Kamat
Clinical Genitourinary Cancer 16 (4), e909-e917, 2018
152018
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas
AR Macalalad, M McAuliffe, H Yang, A Kageleiry, Y Zhong, EQ Wu, ...
Current Medical Research and Opinion 31 (3), 537-545, 2015
142015
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
RL Slater, Y Lai, Y Zhong, H Li, Y Meng, BH Moreno, JL Godwin, T Frenkl, ...
Journal of Medical Economics 23 (9), 967-977, 2020
122020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
AG Bensimon, Y Zhong, U Swami, A Briggs, J Young, Y Feng, Y Song, ...
Current medical research and opinion 36 (9), 1507-1517, 2020
112020
Physician experiences and preferences in the treatment of HR+/HER 2− metastatic breast cancer in the United States: a physician survey
PL Lin, Y Hao, J Xie, N Li, Y Zhong, Z Zhou, JE Signorovitch, EQ Wu
Cancer Medicine 5 (2), 209-220, 2016
102016
Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden
T Srivastava, VS Prabhu, H Li, R Xu, N Zarabi, Y Zhong, JM Pellissier, ...
European urology oncology 3 (5), 663-670, 2020
82020
Costs of care for patients receiving chemotherapy for advanced bladder cancer
AM Kamat, X Cao, J He, Y Zhong, AY Shah, K Flannery
J Clin Pathways 3 (10), 63-70, 2017
82017
Are price discounts on sugar-sweetened beverages (SSB) linked to household SSB purchases?–a cross-sectional study in a large US household and retail scanner database
Y Zhong, AH Auchincloss, MF Stehr, BA Langellier
Nutrition journal 20 (1), 1-12, 2021
52021
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer
N Li, Y Hao, J Xie, PL Lin, Z Zhou, Y Zhong, JE Signorovitch, EQ Wu
Current Medical Research and Opinion 31 (8), 1573-1582, 2015
42015
Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder
ZY Zhou, S Sun, P Chopra, Y Zhong, T Totev, J Signorovitch
Journal of Medical Economics 18 (11), 919-929, 2015
32015
Real world treatment costs and resource utilization among patients with metastatic bladder cancer
K Flannery, X Cao, J He, Y Zhong, AY Shah, A Kamat
Annals of Oncology 28, v400, 2017
22017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20